Clarity Pharmaceuticals Ltd., a clinical-stage radiopharmaceutical company, has announced the successful completion of participant recruitment for the Co-PSMA trial, led by Prof Louise Emmett at St Vincent's Hospital Sydney. This study is evaluating Clarity's diagnostic product, 64Cu-SAR-bisPSMA, against the standard-of-care 68Ga-PSMA-11 in detecting prostate cancer recurrence in patients with low prostate-specific antigen $(PSA)$ levels who are candidates for curative salvage therapy. The results of this head-to-head trial are anticipated in the future. The company is also conducting two Phase III registrational trials, CLARIFY and AMPLIFY, based on positive data from previous trials, PROPELLER and COBRA. Clarity is actively recruiting for the CLARIFY trial and preparing to open enrolment for the AMPLIFY trial at St Vincent's Hospital Sydney.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.